Abstract

Fluticasone, a potent synthetic glucocorticoid, is widely used in the management of inflammatory and allergic conditions such as asthma, allergic rhinitis, and Chronic Obstructive Pulmonary Disease (COPD). Understanding the pharmacokinetics of fluticasone is essential for optimizing its therapeutic efficacy and ensuring patient safety. This abstract provides a concise overview of fluticasone pharmacokinetics, elucidating its Absorption, Distribution, Metabolism, and Excretion (ADME) processes. Fluticasone exhibits rapid absorption following inhalation or intranasal administration, with minimal systemic exposure due to extensive first-pass metabolism. Its distribution is primarily limited to tissues with high glucocorticoid receptor expression, and it undergoes hepatic metabolism mediated by cytochrome P450 enzymes, leading to the formation of inactive metabolites. Fluticasone and its metabolites are predominantly eliminated via renal and fecal routes. Understanding fluticasone pharmacokinetics informs dosing regimens, route of administration, and formulation selection, facilitating the optimization of therapeutic outcomes in patients with inflammatory and allergic conditions. As fluticasone continues to play a pivotal role in respiratory and allergic disease management, unraveling its pharmacokinetic dynamics remains essential for guiding clinical practice and enhancing patient care.